Drug intelligence / Profile preview

warfarin placebo

Development stage: Unknown
Lead developer: University of Wisconsin
Modality: Small Molecules
Administration: Oral

Overview

Warfarin placebo is a pharmacologically inactive substance used as a control in clinical research. Specifically, in the Warfarin-Aspirin Recurrent Stroke Study (WARSS) led by Columbia University, it was utilized in a double-blind, double-dummy trial design to compare the efficacy of warfarin against aspirin for the prevention of recurrent ischemic stroke. The placebo was manufactured to be indistinguishable from the active 2mg scored warfarin tablets to ensure the integrity of the study's blinding. The WARSS trial ultimately found no significant difference between warfarin and aspirin in preventing recurrent stroke or death over a two-year period.

Other names: Warfarin placebo

Targets

VKORC1L1VKORC1 (Vitamin K epoxide reductase complex subunit 1)

Beyond the preview

Go deeper on warfarin placebo.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on warfarin placebo.

Explore the full profile